Ignorance of the medical community towards the effects of quinolones
Posted Tue, 02/03/2009 - 19:17 by FQHelp
The fact that Cipro and quinolones can cause permanent, untreatable tendon damage as highlighted by the need for a black box warning, that leaves patients with crippling untreatable pain, is only the tip of the iceberg when it comes to the other severe and permanently disabling adverse reactions that Cipro and other quinolones can inflict. The product information sheets provided by quinolone manufacturers also fail to indicate that some individuals will suffer from multiple adverse reactions that will become permanent and untreatable.
— DBCipro, White Plains, NY
Read more
Posted Mon, 02/02/2009 - 21:51 by FQHelp
The Chicago teen-ager was also 16 when a physician told her mother to give her Levaquin, according to the girl's sister.
The sister, Mrs. Teri Noto of Roselle, Ill., said the teen-ager did not get through the full course of daily 500-milligram Levaquin pills.
"After five days, it was as if a bomb went off in her body," said the sister. "She collapsed at school and had to be half-carried out of the building."
Read more
Posted Mon, 02/02/2009 - 18:05 by FQHelp
Floxin has also a distinctive profile: many times floxin causes extremely delayed reactions at around the 18 months mark. Many persons take floxin without clear side effects, but after one and a half years, a full adverse reaction develops with plenty of floxing symptoms, in many cases of similar intensity to an intermediate reaction.
(Note that Levofloxacin is the same chemical as Ofloxacin, the atoms and chemical formula is exactly the same, only that Levofloxacin is shaped to be almost double in potency)
Posted Mon, 01/26/2009 - 11:24 by FQHelp
Of the 712 [pediatric] subjects evaluable for safety, 275 (52%) levofloxacin-treated subjects experienced one or more adverse event... Serious adverse events were reported in 33 (6%) levofloxacin-treated subjects...Two serious adverse events in levofloxacin-treated subjects resulted in fatal outcomes.
— John Bradley, M.D., Children’s Hospital and Health Center, San Diego, CA
Posted Sun, 01/25/2009 - 20:48 by FQHelp
The risk-benefit assessment indicates that levofloxacin is only appropriate in pediatric patients for treatment of inhalational anthrax (post-exposure).
Posted Sat, 01/24/2009 - 22:08 by FQHelp
"Doctors fail to realise that these drugs have a proven history of severe toxicity. They are not and cannot be considered first line agents, but drugs of absolute last resort."
Posted Thu, 01/22/2009 - 21:23 by FQHelp
On my 23rd birthday I started ciproI only took 3 doses of cipro in total before realizing what was happening… I went from being a very healthy 23 year old male who was athletic for over 10 years doing Karate, Yoga, Football, Judo and other sports, I eat an extremely healthy diet, no bad foods at all, and generally take care of myself in everyway possible, I have never drank alcohol and never smoked… I have all the blood tests and other tests to prove how healthy I was.
Read more
Posted Thu, 01/22/2009 - 21:19 by FQHelp
Fluoroquinolone antibiotics have damaged many people. I know of this severe damage on a personal level since I suffered such and adverse reaction to the fluoroquinolone antibiotic Levaquin myself 22 months ago. Since then I have had daily pain and disability of my nervous and musculoskeletal systems and for several months had endocrine and gastrointestinal problems as well.
Read more
Posted Thu, 01/22/2009 - 20:23 by FQHelp
The newest fluoroquinolones may benefit some patients, but their ease of use may promote indiscriminate use. The risk/benefit ratio of the fluoroquinolones should be carefully considered, and these drugs should be prescribed cautiously, since better-tolerated, less expensive drugs can usually be prescribed instead.
Posted Thu, 01/22/2009 - 20:12 by FQHelp
One day after juvenile rats were given a single dose of ofloxacin and pefloxacin, their Achilles tendons showed alterations of the collagen, edema, and an inflammatory infiltrate...
— J. Michael Casparian, MD, Michael Luchi, MD, Department of Medicine, University of Kansas
Read more